1. Scrip
  2. >>Business
  3. >>Deals

Almirall Plots M&A Moves Ahead Of Lebrikizumab Approval

Raises €200m For Bolt-Ons Or Licensing

 
• By Kevin Grogan

The Spanish group has been fairly quiet on the dealmaking front of late but the proceeds of a significant capital raise have been earmarked to help “swiftly execute inorganic growth opportunities.”

Almirall
• Source: Almirall

Most of the focus at Almirall SA is on securing EU approval for the closely watched atopic dermatitis drug lebrikizumab but the Spanish drugmaker is also looking to bring in other assets to feed the pipeline.

As part of that strategy, Almirall has closed a €200m capital raise through the issue of around 24.4 million new shares

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from Business